FIELD: medicine.
SUBSTANCE: invention relates to the field of cellular biology and medicine, in particular, to a system for directed delivery and to a method for producing such a system. Said system comprises a cell constituting a CD45+ leukocyte, selected, in particular, from a CD45+ monocyte, a CD45+ monocyte macrophage, a CD45+ lymphocyte, or a CD45+ granulocyte. Said cell therein contains a complex of at least one iron-binding protein and a pharmaceutically active substance and/or label.
EFFECT: invention ensures delivery of pharmaceutically active substances and/or labels to cells in poorly or non-vascularised areas; reduction in the side effects of medicinal products due to the targeted delivery thereof; and higher effectiveness of treatment by lower doses of medicinal products due to the targeted delivery thereof.
41 cl, 27 dwg, 18 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS AND ANTIBODIES FOR IMMUNE RESPONSE MODULATION | 2016 |
|
RU2757489C2 |
| MODIFIED ADENYLATE CYCLASE BORDETELLA CONTAINING CD11b/CD18 INTERACTION DOMAIN OR CD11B/CD18 INTERACTION DOMAIN DEFICIENT, AND ITS APPLICATION | 2004 |
|
RU2421241C2 |
| FUSED PROTEIN SIRPΑ-4-1BBL AND METHODS OF USING SAME | 2018 |
|
RU2769769C2 |
| HUMANISED MOUSE M-CSF | 2012 |
|
RU2577978C2 |
| HUMANIZED M-CSF MICE | 2020 |
|
RU2819731C2 |
| ANGIOGENESIS INHIBITION | 2008 |
|
RU2471498C2 |
| METHOD FOR OBTAINING UP-REGULATING PD-L1 EXPRESSION, POLYPEPTIDES, A CONJUGATE, A FUSED POLYPEPTIDE, A COMPOSITION AND A COMBINATION TO PROVIDE UP-REGULATING EXPRESSION OF PD-L1 | 2016 |
|
RU2734169C2 |
| REPROGRAMMING HUMAN ENDOTHELIUM IN HEMATOPOIETIC PRECURSORS OF MULTIPLE LINES OF DIFFERENTIATION USING CERTAIN FACTORS | 2014 |
|
RU2691062C2 |
| USE OF PEPTIDE FOR TREATMENT OF CARDIOVASCULAR DISEASES | 2013 |
|
RU2672341C2 |
| HUMANISED M-CSF MICE | 2012 |
|
RU2730643C2 |
